INTRAUTERINE COPPER CONTRACEPTIVE IMPLANT (IUCI)

GyneFix(R), conceived in 1985, was developed to minimize three major p roblems frequently associated with discontinuation of IUD use : expuls ion, bleeding and pain. Since the initial clinical investigations, ove r 10,000 women years of experience and up to 8 years of follow-up in i nternational, multicenter, non-comparative and comparative clinical tr ials, including a large proportion of nulligravid/nulliparous women, h ave been collected The following conclusions were reached : 1. The uni que design characteristics of GyneFix (frameless, flexible and fixed t o the fundus of the uterus) have resulted in optimal tolerance and alm ost complete absence of expulsion. The result is enhanced effectivenes s (comparable to OCs and male/female sterilization) and a high rate of continued use. GyneFix reduces the IUD-failure rate to a minimum and is, therefore, a welcome reversible alternative to OCs and female surg ical contraception. 2. Frameless and flexibility explain the absence o f side-effects and adverse events caused by dimensional incompatibilit y between the frame of conventional IUDs and the uterine cavity and ma y also explain the absence of PID and ectopic pregnancies in any of th e clinical studies. 3. Insertion of GyneFix, with or without local ana esthesia, is easily accomplished in the office in a few minutes. Remov al is easy, quick and painless. 4. GyneFix is an equally effective and well accepted method for nulliparous women.